Open AccessPersonalized Approach to Cancer Treatment–Related Cardiomyopathy
Author(s) -
Jeremy Slivnick,
Ajay Vallakati,
Daniel Addison,
Alexander Wallner,
Matthew Tong
Publication year - 2020
Publication title -
current heart failure reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.036
H-Index - 39
eISSN - 1546-9549
pISSN - 1546-9530
DOI - 10.1007/s11897-020-00453-3
Subject(s) - cardiac surgery , medicine , vascular surgery , cardiomyopathy , abdominal surgery , cardiothoracic surgery , cancer , cardiology , surgery , heart failure
Cancer treatment-related cardiotoxicity (CTRC) represents a significant cause of morbidity and mortality worldwide. The purpose of our review is to summarize the epidemiology, natural history, and pathophysiology of cardiotoxicity-related to cancer treatment. We also summarize appropriate screening, surveillance, and management of CTRC. While cardiotoxicity is characteristically associated with anthracyclines, HER2-B antagonists, and radiation therapy (XRT), there is growing recognition of toxicity with immune checkpoint inhibitors (ICI), tyrosine kinase inhibitors, and proteasome inhibitors.